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Abstract 
Diagnostic characteristics of nodular lymphocyte-
predominant Hodgkin lymphoma (NLPHL): nodular 
or nodular and diffuse proliferation of scattered 
lymphocyte predominant (LP) tumour cells within a 
background reminiscent of primary or secondary 
lymphoid follicles. Six different patterns: A) 
'classical' nodular, B) serpiginous/interconnected 
nodular, C) nodular with prominent extra-nodular 
LP cells, D) T-cell-rich nodular, E) diffuse with a T-
cell-rich background, and F) diffuse, B-cell-rich 
pattern.  
Typical histopathologic patterns in NLPHL include 
patterns A and B. Both of these patterns show a 
predominantly nodular growth, with LP cells located 
within the nodules. So called "histopathologic 
variants" are defined by prominent extranodular LP 
cells associated to patterns C to F. "Histopathologic 
variants" may be associated with advanced stage 
disease and higher relapse rate. Assessing 
"histopathologic variants" patterns in NLPHL may 
be useful for the management of the patients. 
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Identity 
Other names: Lymphocyte-predominant HL 
Clinics and pathology 
Disease 
Nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL) is a distinct subtype of 
Hodgkin lymphoma (HL), usually associated with an 
indolent course and presenting in the early stages of 
the disease (Anagnostopoulos et al., 2000). 
Phenotype/cell stem origin 
Cell origin 
Tumour cells are antigen-selected mutating germinal 
center (GC) B cells. This origin is supported by 
The expression of BCL6 and CD40 by tumour cells 
(Carbone et al., 1995; Liso et al., 2006). 
The presence of CD4+, CD57+, PD1+ T cells 
surrounding the tumour cells (Poppema et al., 2008). 
The presence of a follicular dendritic cell 
meshowork within the tumour nodules (Mason et al., 
1994 ; Carbone and Gloghini, 2012) 
The gene expression profile (Brune et al., 2008). 
Rearranged, clonal and mutated (ongoing) Ig genes 
of tumour cells (Marafioti et al., 1997; Küppers, 
2011). 
Phenotype 
LP cells profile: CD45+, CD20+, CD40+, CD79a+, 
CD75+, BCL6+, IRF4/MUM1+, and OCT2+, 
BOB1+, PAX5+, PU.1+, epithelial membrane 
antigen+. CD15 and CD30 are usually negative 
(Poppema et al., 2008). 
Nodules compositon: CD20+ and IgD+ small B 
cells, CD3+ and CD4+ T cells and histiocytes. 
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The background of the nodules also includes an 
increase in GC-derived CD57+, IRF4/MUM1+, and 
PD-1+ T-cells populations which form a rim around 
LP cells (Carbone and Gloghini, 2012). 
Epidemiology 
About 5% of all HL cases are classified as NLPHL. 
Males are more commonly affected than females 
(male-female ratio, 3:1). The median age at 
presentation is about 40 years. 
Clinics 
NLPHL is a neoplasm usually associated with a 
favourable clinical course despite a tendency for 
local recurrences. 
Cytology 
NLPHL tumour cells are termed lymphocyte 
predominant (LP) cells. LP cells are large cells with 
multilobated nuclei and scant cytoplasm. They 
contain multiple, not prominent, nucleoli in contrast 
with typical Reed Sternberg cells of classical HL that 
contain huge eosinophilic nucleoli. 
Pathology 
LP tumour cells proliferate within a nodular or  
nodular and diffuse background (Anagnostopoulos 
et al., 2000).  
The tumour nodules are reminiscent of a primary 
follicle containing spherical meshworks of follicular 
dendritic cells (FDCs) admixed with inflammatory 
cells (Mason et al., 1994). 
On morphologic and immunohistologic grounds, six 
patterns are recognizable in NLPHL (Fan et al., 
2003): A) 'classical' nodular, B) 
serpiginous/interconnected nodular, C) nodular with 
prominent extra-nodular LP cells, D) T-cell-rich 
nodular, E) diffuse with a T-cell-rich background, 
and F) diffuse, B-cell-rich pattern. 
Typical histopathologic patterns in NLPHL include 
patterns A and B. Both of these patterns show a 
predominantly nodular growth, with LP cells located 
within the nodules.  
So called "histopathologic variants" include patterns 
from C to F and are associated to prominent 
extranodular LP cells or to B-cell depletion of the 
microenvironment (Hartmann et al. Blood, 2013). 
An additional nodular pattern in which LP cells 
proliferate within a background reminiscent of a 
secondary follicle without invasion of the 
extranodular space has been recognized (Carbone 
and Gloghini, 2012; Gloghini et al., 2015). 










The neoplastic cells are usually EBV negative 
(Anagnostopoulos et al., 2000). 
Treatment 
Early stage disease: treatment with local radiation 
provides disease control and good overall survival 
(Advani and Hoppe, 2015). 
Locally extensive or advanced stages: paradigms 
used for classical HL with similar outcomes (Advani 
and Hoppe, 2015). Excellent response rates (but 
increased relapse rates) observed with single agent 
rituximab. Promising data observed with R-CHOP 
(Advani and Hoppe, 2013; Younes et al., 2014). 
Relapsed disease: single agent rituximab is a 
reasonable choice because of excellent tolerability 
(Advani and Hoppe, 2015). 
Evolution 
Transformation to diffuse large B-cell lymphoma (T-
cell/histiocyte rich large B-cell lymphoma). 
Prognosis 
Favourable clinical course despite a tendency for 
local recurrences (Advani and Hoppe, 2013). 
Compared with "typical NLPHL", "histopathologic 
variants" are associated with more advanced disease 
and a higher relapse rate (Hartmann et al. Blood, 
2013). 
Genetics 
Translocation involving the BCL6 protooncogene 
(Liso et al., 2006). Strong NFKB activity (Küppers, 
2011). Aberrant somatic hypermutation of multiple 
proto-oncogenes (PIM1, RHOH (TTF), MYC, and 
PAX5) in a fraction of cases. Most of mutations are 
on the 5' untranslated regions of the genes (Liso et 
al, 2006). Mutation in SOCS1 (Küppers, 2011).  
BAG6 (BAT3), HIGD1A, and UBD (FAT10) gene 
espression (Hartmann et al. PlosOne, 2013). 
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